Opinion

Video

Treatment Regimen Considerations

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPAAmir Ali, PharmD, BCOP

Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements

Video content above is prompted by the following:

  • What factors around administration logistics and supportive care requirements (eg, premedications, infusion reactions) do you consider when sequencing regimens for transplant-eligible patients?
  • (Dr Adams) What patient characteristics would lead you to consider a quadruplet regimen like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) compared with a triplet regimen like VRd or KRd (carfilzomib, lenalidomide, and dexamethasone)?
Related Videos
3 KOLs are featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Pharmacist talking to a patient with cancer
Related Content
Image Credit: © Nihad - stock.adobe.com
September 28th 2024

Small Molecule Drugs Remain Vital in Addressing Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Image Credit: © Tatiana Shepeleva - stock.adobe.com
September 28th 2024

Immunotherapy Evolution Continues With Innovative Approaches to Multiple Myeloma Treatment

Alexandra Gerlach, Associate Editor
Image Credit: © Animager - stock.adobe.com
September 27th 2024

Overcoming Treatment Challenges in Multiple Myeloma: Bispecific Antibodies and CAR T-Cell Therapy

Alexandra Gerlach, Associate Editor
Daratumumab Plus Lenalidomide Maintenance in Transplant-Eligible Newly-Diagnosed MM Improves MRD Negativity
September 27th 2024

Daratumumab Plus Lenalidomide Maintenance in Transplant-Eligible Newly-Diagnosed MM Improves MRD Negativity

Aislinn Antrim, Assistant Managing Editor
A vector representation of multiple myeloma cells.
September 27th 2024

Talquetamab-Daratumumab-Pomalidomide Combination Led to Durable Response in Patients With Relapsed/Refractory Multiple Myeloma

Luke Halpern, Assistant Editor